Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001137439-25-000994
Filing Date
2025-08-05
Accepted
2025-08-05 15:19:58
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 4885
  Complete submission text file 0001137439-25-000994.txt   6708
Mailing Address THREE INTERNATIONAL TOWERS LEVEL 24, 300 BARANGAROO AVENUE SYDNEY NSW C3 2000
Business Address THREE INTERNATIONAL TOWERS LEVEL 24, 300 BARANGAROO AVENUE SYDNEY NSW C3 2000 01161298780088
KAZIA THERAPEUTICS LTD (Subject) CIK: 0001075880 (see all company filings)

EIN.: 000000000 | State of Incorp.: C3 | Fiscal Year End: 0630
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-50612 | Film No.: 251184515
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 8567 HUMMINGBIRD COMMERCE TOWNSHIP MI 48382
Business Address 8 WOLFEBORO RD ETNA NH 03750 734-770-0040
Dauntless Investment Group, LLC (Filed by) CIK: 0002044285 (see all company filings)

EIN.: 994741394 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A